-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师总结如下:伯克希尔哈撒韦公司2026年第一季度运营每股收益为5.26美元,高于此前预期的4.47美元,也高于我们此前预测的5.10美元和市场普遍预期的5.05美元,运营收入增长4.4%。税前运营利润翻了一番多,利润率从5.6%扩大至13%,但GEICO的承保业绩恶化,综合比率从79.8%上升至87.3%。我们认为,在经历了2025年不足1%的收入增长后,营收温和增长的恢复将令投资者感到安心,尽管保险业务表现喜忧参半。首席执行官格雷格·阿贝尔在其首次年度股东大会上重申了伯克希尔哈撒韦的收购战略和股票回购政策,但并未对预先设定的资本配置做出任何承诺。鉴于伯克希尔哈撒韦公司拥有超过3800亿美元的现金,且2025年计划零回购,预计其2026年第一季度仅回购了2.35亿美元的股票,因此我们估计该公司可能会将800亿至1000亿美元用于收购。我们维持对该公司2026年3%至7%的营收增长预期,但考虑到其雄厚的现金储备,我们预计投资者会期待该公司采取更积极的资本部署策略。
Related Articles
Research Alert: Berkshire Q1 Eps Tops Expectations, With Mixed Insurance Results
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Berkshire's Q1 2026 operating EPS of $5.26 vs $4.47 topped our $5.10 estimate and $5.05 consensus view, with operating revenues rising 4.4%. Pretax operating profits more than doubled as margins widened to 13% from 5.6%, though GEICO's underwriting results deteriorated with combined ratio rising to 87.3% from 79.8%. We believe the resumption of modest top-line growth after 2025's sub-1% revenue growth will reassure investors, despite mixed insurance performance. CEO Greg Abel reiterated Berkshire's acquisition strategy and share buyback policy at his debut annual meeting, though provided no commitment to predetermined capital allocation. With cash exceeding $380B and only $235M in Q1 buybacks after zero repurchases in 2025, we estimate Berkshire could allocate $80-100B to acquisitions. We keep our 3%-7% revenue growth forecast for 2026, though expect investors hoped for more aggressive capital deployment given the substantial cash position.
Research Alert: CFRA Maintains Hold Rating On Shares Of Sofi Technologies, Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month target by $4 to $18, applying a P/E of 17.8x our 2028 EPS view vs. SOFI's 71.2x three-year historical forward P/E average. We keep our 2026 EPS estimate at $0.58, 2027's at $0.81, and 2028's at $1.01. We expect robust member and product growth, fueled by key initiatives like crypto and the SoFi Plus relaunch, to support sustained double-digit revenue expansion. The relaunched SoFi Plus introduces a paid subscription to fuel cross-selling, while the crypto initiative leverages its unique, bank-issued stablecoin to become a core infrastructure provider for digital assets.However, this outlook is reflected in a rich valuation that leaves minimal room for execution missteps. We remain neutral, as a sustained high-rate environment could stress consumers and impact credit performance, a key risk given the company's large personal loan portfolio. Management's decision to not raise full-year guidance, despite a strong quarter, balances strategic investments against macroeconomic uncertainties.
Research Alert: CFRA Maintains Buy Rating On Shares Of Tenet Healthcare
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month target price to $200 from $260, 11.4x our 2026 EPS estimate (up to $17.56 from $17.33; 2027 estimate up to $18.00 from $17.85), a discount to the company's three-year historical forward average of 12.9x. We think THC's valuation balances recent deleveraging efforts and a stronger margin profile than in previous years against policy headwinds, including cuts to Medicaid coverage under the OBBBA legislation and the recent expiration of ACA enhanced premium tax credits, which increases risk of higher uncompensated care. Same-facility ACA exchange admissions fell 10% Y/Y in Q1, and THC guides for a 20% reduction in ACA exchange patient volumes for 2026 and anticipates a negative $250 million impact on adjusted EBITDA. While we expect THC to revisit annual guidance in Q2 earnings, at which point a clearer picture of the insurance coverage landscape is likely, we look favorably on the company maintaining its annual inpatient/outpatient volume guidance for now.